Burchfield v. United States

168 F.3d 1252, 1999 U.S. App. LEXIS 3190, 1999 WL 104438
CourtCourt of Appeals for the Eleventh Circuit
DecidedMarch 2, 1999
Docket98-2024
StatusPublished
Cited by50 cases

This text of 168 F.3d 1252 (Burchfield v. United States) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Burchfield v. United States, 168 F.3d 1252, 1999 U.S. App. LEXIS 3190, 1999 WL 104438 (11th Cir. 1999).

Opinion

KRAVITCH, Senior Circuit Judge:

A plaintiff who sues under the Federal Tort Claims Act, 28 U.S.C. §§ 2671 et seq. (“FTCA”), must first present his or her claim to the appropriate federal agency. 28 U.S.C. § 2675(a). This case requires us to determine the amount of information that this claim must contain. Appellant Boyd Burch-field (“Burchfield”) sued the United States pursuant to the FTCA, alleging that the negligence of employees of the Department of Veterans Affairs (“VA”) led to his severe osteoporosis. The district court held that it lacked subject matter jurisdiction over the complaint because the claim that Burchfield had presented to the VA did not satisfy 28 U.S.C. § 2675(a). We conclude that Burch-field’s claim contained sufficient information to meet the presentment requirements of section 2675(a), and therefore reverse and remand for further proceedings.

I.

While on active duty with the United States Army in 1968, Burchfield developed a tumor of the pituitary gland. Army doctors operated to remove the tumor, but it reoccurred in 1986 and Burchfield underwent five additional surgeries, the last in 1990. As a result of the surgeries, Burchfield developed panhypopituitarism (non-functioning of the pituitary gland), which caused his body to stop producing cortisone, thyroid hormone, and testosterone. To replace some of these natural hormones his doctors, VA employees, prescribed a corticosteroid, Pred-nisone. As far as the record before us shows, Burchfield’s doctors did not accompany this prescription with a program of dietary supplements to combat osteoporosis, such as Vitamin D, calcium or calcitonin. The doctors also prescribed injectable testosterone, which can help to restore sexual function and prevent osteoporosis. After a short time Burchfield discontinued the testosterone treatments, telling his doctors that he disliked their side effects and that he was not interested in regaining sexual function. It is not clear whether Burchfield’s doctors informed him that injectable testosterone treatments could help prevent osteoporosis.

*1254 Beginning as early as 1988, Burchfield developed osteoporosis, which had become severe by 1996. As a result, he suffered various injuries, including rib and sternal fractures and collapsed vertebrae, and is at risk of further injury.

Pursuant, to the requirements of 28 U.S.C. § 2675(a), 1 Burchfield filed an administrative claim on Standard Form 95 with the VA on January 17,1996. The claim stated:

Beginning August of 1990 and in subsequent years, physicians employed by the Department of Veterans Affairs prescribed a medication for Mr. Burchfield, predni-sone. Mr. Burchfield’s use of this medicine caused him to develop osteoporosis, resulting in severe and continuing maladies and injuries, including but not limited to the collapse or fracture of several vertebrae and ribs.... These injuries resulted from negligence of the Department’s agents. 2

The claim listed thirteen doctors who had treated Burchfield. After six months, during which the VA failed to make a final disposition of the claim, Burchfield filed suit in district court. His complaint alleged, inter alia, that osteoporosis was a “known and anticipated effect! ] of corticosteroid therapy” 3 and that his doctors were negligent in failing to initially diagnose osteoporosis, to monitor him for the condition during his treatment, and to administer a bone strengthening regimen. 4 At the bench trial, Burchfield’s medical expert, Dr. Thomas Zizic, stated that prescribing the corticosteroid Prednisone did not in itself deviate from the standard of care. 5 He testified, however, that Burchfield’s doctors deviated from the standard of care by treating him with Pred-nisone without taking certain other steps, such as performing initial baseline tests for osteoporosis and prescribing such supplements as calcium and Vitamin D to counteract the treatment’s effects. 6

After Dr. Zizic testified, the district court addressed the issue of its jurisdiction under the FTCA. It found that Burchfield’s administrative claim had alleged only that the VA’s doctors were negligent in prescribing Predni-sone, while at trial Burchfield had raised a “significant[ly] different claim! ]” that the VA had “caus[ed] or contributed] to the exacerbation of osteoporosis by failing to diagnose it properly and by failing to treat it properly.” 7 On the basis of this distinction, the district court held that Burchfield had failed to meet the requirements of section 2675(a) by putting the VA on notice of his allegations, and that it therefore lacked subject matter jurisdiction over Burchfield’s claim. The court entered judgment as a matter of law in favor of the United States.

II.

We review a district court’s grant of judgment as a matter of law de novo. Morris v. Crow, 117 F.3d 449, 455 (11th Cir.1997).

A plaintiff bringing a claim against the United States under the FTCA must first present the claim to the appropriate federal agency and wait for the agency to finally deny it. An agency’s failure to dispose of a claim within six months is deemed to be a final denial. See 28 U.S.C. § 2675(a). A district court only has jurisdiction over an FTCA action if the plaintiff has met section *1255 2675(a)’s requirements. See Bush v. United States, 703 F.2d 491, 494 (11th Cir.1983).

To satisfy section 2675(a), a claimant must do two things: “(1) give[ ] the [appropriate] agency written notice of his or her claim sufficient to enable the agency to investigate and (2) placet ] a value on his or her claim.” Adams v. United States, 615 F.2d 284, 289 (5th Cir.), decision clarified on denial of reh’g, 622 F.2d 197 (5th Cir.1980). 8 Because Burchfield’s administrative claim placed a dollar value on his alleged damages, 9 the only issue before us is whether his claim gave notice of the allegations he made at trial.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
168 F.3d 1252, 1999 U.S. App. LEXIS 3190, 1999 WL 104438, Counsel Stack Legal Research, https://law.counselstack.com/opinion/burchfield-v-united-states-ca11-1999.